Diabetes

The company is investing in PhysioLogic Devices, a firm developing an implantable intraperitoneal insulin delivery system.

Dexcom acknowledged in a Facebook post that customers were disappointed in the communication shortfalls following a major server outage that occurred over the holiday weekend.

Abbott and Tandem investors reacted favorably to the companies' diabetes partnership news, but DexCom investors see the deal as a competitive threat to DexCom's G6 continuous glucose monitoring device.

The San Diego-based company continues to shape its CGM portfolio as it faces off against some stiff competition in the market.

Medtronic and Abbott each announced separate collaboration agreements this week that demonstrate the importance of medical device companies and pharmaceutical companies working together to improve diabetes management. Medtronic is working with...

Dexcom CEO Kevin Sayer says CGM is quickly becoming standard of care in diabetes.

The Seattle-based company is making significant pre-clinical progress with its wearable CGM. However, the space is dominated by top industry players like Dexcom, Abbott Laboratories, Senseonics, and Medtronic.

CEO Miles White talks about the unprecedented scale-up to support the Freestyle Libre, and hints that the blockbuster product could someday be a wearable.